Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that affects
women of childbearing age, multiplying pregnancy complications 2-4 times. According to …

Background SLE is an autoimmune disease typically affecting women of childbearing age
that can be associated with significant maternal and fetal morbidity. Belimumab is a biologic …

Background Systemic lupus erythematosus (SLE) is associated with poor pregnancy
outcomes and complications. Belimumab can significantly improve disease activity in …

Background: Belimumab (BEL) is a monoclonal antibody approved for SLE treatment but
few data are available about its use before or during pregnancy. Objectives: Our study aims …

A recent report from the Belimumab Pregnancy Registry (NCT01532310) analysed available
data on the consequences of belimumab (BEL) use in pregnant women with systemic lupus …

Since its approval for the management of systemic lupus erythematosus (SLE), belimumab
has been widely used. However, its pregnancy safety profile has been underinvestigated …

Background Pregnancy can lead to flares in systemic lupus erythematosus (SLE), and the
presence of SLE in pregnancy could lead to a poor outcome for the mother and the fetus …

Objective Describe available data on birth defects and pregnancy loss in women with
systemic lupus erythematosus (SLE) exposed to belimumab. Methods Data collected from …

Introduction The first biologic authorized for systemic lupus erythematosus (SLE) up to this
date, belimumab, is currently not recommended for use during pregnancy due to lack of …

Objectives Systemic lupus erythematosus (SLE) predominantly occurs in women of child-
bearing age. Selecting drugs for pregnant SLE patients has always been a difficult choice …